IRICoR and IRIC participate in RQRM’s 1st Forum on drugs, “From Molecule to Patient”

Plateforme_Chimie médicinaleThe Institute for Research in Immunology and Cancer — Commercialization of Research (IRICoR) and the Institute for Research in Immunology and Cancer (IRIC) both located at the Université de Montréal (UdeM) will participate in the 1st Forum on drugs, “From Molecule to Patient” of the Réseau québécois de recherche sur les médicaments (RQRM), to be held on June 1, 2015, in Québec City.

More particularly, IRICoR’s chief executive officer Dr. Michel Bouvier and his colleague Dr. Nadine Beauger, vice-president, scientific liaison, are co-organizing the session on partnerships between academia and industry. In collaboration with Elizabeth Douville from Amorchem, Diane Gosselin from CQDM and Philippe Walker from NÉOMED, they will participate in the presentation on “L’écosystème québécois en partenariats académie-industrie : une vision intégrée” (The Québec ecosystem in academia-industry partnerships: an integrated vision) in collaboration with.

In addition, Dr. Guy Sauvageau, principal investigator at the IRIC and his colleague Dr. Anne Marinier, principal investigator and director of medicinal chemistry, will be delivering a speech entitled “Réussite du passage R-D à l’étude de phase I, une molécule au potentiel inouï” (Successful R&D transition to the phase I trial, a molecule of outstanding potential) during the session on research in translational medicine.

Given the vital role played by drugs in the prevention and management of acute and long-term diseases, this event should prove to be a prime venue for the discussion on the importance of academic and industrial drug discovery partnerships.

For information about this conference, click here.

About the Institute for Research in Immunology and Cancer

An ultra-modern research hub and training centre located in the heart of the Université de Montreal, the Institute for Research in Immunology and Cancer (IRIC) was created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this disease. IRIC operates according to a model that is unique in Canada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer.  For more information: www.iric.ca

About the Institute for Research in Immunology and Cancer — Commercialization of Research

The Institute for Research in Immunology and Cancer — Commercialization of Research (IRICoR) is a not-for-profit organization at the Université de Montréal (UdeM) whose mission is to accelerate the discovery, development and commercialization of innovative drugs and therapies originating in particular at the Institute for Research in Immunology and Cancer (IRIC), at other UdeM scientific research units, and with external collaborators. IRICoR invests in projects that are especially ground-breaking, identifies the best development partners for commercially promising projects, thus ensuring a speedy transition from university research to the market.  For more information: www.iricor.ca

Information:
Manon Pepin
Communications and Media Relations Director
Institute for Research in Immunology and Cancer│IRIC
Université de Montréal
(514) 343-7283│manon.pepin@umontreal.ca

 

 

© 2008-2020 IRICoR